Veeva Systems
VEEV
Market cap $45.3B

277.40 USD

-4.03

1.43%

Updated Jun 20, 1:01 PM EDT

1 day

-1.43%

5 days

-0.31%

1 month

15.21%

3 months

17.62%

6 months

23.76%

Year to date

31.73%

1 year

50.92%

5 years

16.11%

10 years

915.00%

About: Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Employees: 7,291

Healthcare Health Information Services

0

Funds holding %

of 7,302 funds

0

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

132% more call options, than puts

Call options by funds: $371M | Put options by funds: $160M

38% more first-time investments, than exits

New positions opened: 127 | Existing positions closed: 92

31% more funds holding in top 10

Funds holding in top 10: 16 [Q4 2024] → 21 (+5) [Q1 2025]

12% more capital invested

Capital invested by funds: $27.3B [Q4 2024] → $30.4B (+$3.15B) [Q1 2025]

2% more funds holding

Funds holding: 980 [Q4 2024] → 998 (+18) [Q1 2025]

0.96% more ownership

Funds ownership: 79.78% [Q4 2024] → 80.74% (+0.96%) [Q1 2025]

2% less repeat investments, than reductions

Existing positions increased: 357 | Existing positions reduced: 363

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$210

24%

downside

Avg. target

$283

2%

upside

High target

$329

19%

upside

13 analyst ratings

9 positive

69%

3 neutral

23%

1 negative

8%

Mizuho Steven Valiquette	6%upside $295	Outperform Maintained	2 Jun 2025
Citigroup Tyler Radke	19%upside $329	Buy Maintained	30 May 2025
Wells Fargo Stan Berenshteyn	8%upside $300	Overweight Maintained	29 May 2025
Stifel David Grossman	6%upside $295	Buy Maintained	29 May 2025
UBS Karl Keirstead	3%upside $285	Neutral Maintained	29 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 36 articles about VEEV published over the past 30 days

Veeva Systems: The Strong Quarter May Be A First Of Many To Come

Veeva Systems delivered a standout quarter, raising guidance and demonstrating accelerating growth, with Crossix and the company's Commercial Cloud, overall, driving strong revenue and margin outperformance. Despite macro and competitive risks, I see Veeva's competitive position strengthening, especially as migrations to Vault CRM and new AI offerings gain traction. Veeva AI, launching in December, is poised to boost growth and productivity, supporting my increased 3-year CAGR estimate to 20% and justifying the premium valuation.

Veeva Systems: The Strong Quarter May Be A First Of Many To Come

Zacks Investment Research

VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma

Veeva Systems launches China Campaign Manager to boost pharma engagement with localized, compliant CRM-driven solutions.

VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma

Zacks Investment Research

Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run?

Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run?

Zacks Investment Research

Why Veeva Systems (VEEV) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Veeva Systems (VEEV) is a Top Momentum Stock for the Long-Term

The Motley Fool

2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility

Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date.

2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility

Zacks Investment Research

Best Momentum Stocks to Buy for June 11th

SSRM, VEEV and BAESY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 11, 2025.

Best Momentum Stocks to Buy for June 11th

Zacks Investment Research

Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?

Zacks Investment Research

New Strong Buy Stocks for June 11th

PROSY, EVR, VEEV, BAESY and SSUMY have been added to the Zacks Rank #1 (Strong Buy) List on June 11, 2025.

New Strong Buy Stocks for June 11th

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed PLEASANTON, Calif. , June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies.

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

Industry focused on automation, connectivity, and reporting for proactive quality management PLEASANTON, Calif. , June 9, 2025 /PRNewswire/ -- The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality management within the next three years to improve compliance and drive innovation.

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

See News Rankings

Charts implemented using Lightweight Charts™